Intelligence / Healthtech / New Clinical Trials / Beijing InnoCare Pharma Tech Co., Ltd.
Beijing InnoCare Pharma Tech Co., Ltd.
3 Nov 2026: Trial registered · Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults Volunteers. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 3 Nov 2026
- Title
- Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults Volunteers
- Conditions
- Inflammatory Bowel Disease(IBD)
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07911982
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Beijing InnoCare Pharma Tech Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Beijing InnoCare Pharma Tech Co., Ltd. in our registers.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.